One of the principal goals of cancer immunotherapy is the development of efficient
therapeutic cancer vaccines that are able to elicit an effector as well as memory T cell …

Many antigens recognized by autologous T lymphocytes have been identified on human
melanoma. Melanoma patients usually mount a spontaneous T cell response against their …

Antibody and T‐cell receptors (TCRs) are the primary recognition molecules of the adaptive
immune system. Antibodies have been extensively characterized and are being developed …

In mouse, a subset of dendritic cells (DCs) known as CD8α+ DCs has emerged as an
important player in the regulation of T cell responses and a promising target in vaccination …

Antigen recognition by the T-cell receptor (TCR) is a hallmark of the adaptive immune
system. When the TCR engages a peptide bound to the restricting major histocompatibility …

The generation of T lymphocytes with specific reactivity against tumor antigens is a
prerequisite for effective adoptive transfer therapies. Melanoma-specific lymphocyte cultures …

The first tumor‐specific shared antigens and the cancer‐germline genes that code for these
antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer …

Purpose: Whole tumor lysates are promising antigen sources for dendritic cell (DC) therapy
as they contain many relevant immunogenic epitopes to help prevent tumor escape. Two …

In the 9 years since its discovery, cancer‐testis antigen NY‐ESO‐1 has made one of the
fastest transitions from molecular, cellular, and immunological description to vaccine and …

T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on
the binding parameters that govern the interactions between T cell receptors (TCRs) and …